Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer by Yoshida, Takahiro et al.
Oncotarget33306www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 22
Effective treatment of ductal carcinoma in situ with a HER-2-
targeted alpha-particle emitting radionuclide in a preclinical 
model of human breast cancer
Takahiro Yoshida1,*,$, Kideok Jin1,*, Hong Song2, Sunju Park1, David L. Huso3,@, Zhe 
Zhang1, Han Liangfeng1, Charles Zhu4, Frank Bruchertseifer5, Alfred Morgenstern5, 
George Sgouros2, Saraswati Sukumar1
1Department of Oncology, Johns Hopkins University School of Medicine, Maryland, USA
2Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Maryland, USA
3Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Maryland, USA
4Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA
5European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany
$Current address: Department of Surgery, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, Japan
*These authors have contributed equally to this work
@Deceased
Correspondence to: Saraswati Sukumar, e-mail: saras@jhmi.edu
George Sgouros, e-mail: gsgouros@jhmi.edu
Keywords: intraductal, radioimmunotherapy, trastuzumab, ductal carcinoma in situ, breast cancer
Received: August 05, 2015    Accepted: March 31, 2016    Published: April 23, 2016
ABSTRACT
The standard treatment for ductal carcinoma in situ (DCIS) of the breast is 
surgical resection, followed by radiation. Here, we tested localized therapy of 
DCIS in mice using the immunoconjugate 225Ac linked-trastuzumab delivered 
through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu, while the 
alpha-emitter 225Ac (half-life, 10 days) delivers highly cytotoxic, focused doses of 
radiation to tumors. Systemic 225Ac, however, elicits hematologic toxicity and at high 
doses free 213Bi, generated by its decay, causes renal toxicity. I.duc delivery of the 
radioimmunoconjugate could bypass its systemic toxicity. Bioluminescent imaging 
showed that the therapeutic efficacy of intraductal 225Ac-trastuzumab (10-40 nCi per 
mammary gland; 30-120 nCi per mouse) in a DCIS model of human SUM225 cancer 
cells in NSG mice was significantly higher (p<0.0003) than intravenous (120 nCi per 
mouse) administration, with no kidney toxicity or loss of body weight. Our findings 
suggest that i.duc radioimmunotherapy using 225Ac-trastuzumab deserves greater 
attention for future clinical development as a treatment modality for early breast 
cancer.
INTRODUCTION
Curing breast cancer is probably best achieved by 
eliminating preneoplasia and initiated cells in the breast 
ductal systems. Recently, the detection of DCIS has 
risen dramatically with the widespread use of screening 
mammography [1, 2]. The local recurrence rate after 
breast conservation therapy for DCIS is 8-14% [1, 2] and 
not negligible. HER-2, a transmembrane tyrosine kinase, 
is over-expressed in 30-40% of DCIS [3–5]. High HER-2 
and/or Ki-67 expression are risk factors of local recurrence 
of DCIS [6].
Since targeted antibodies have successfully 
demonstrated activity in treating HER-2 positive breast 
cancer, conjugated antibodies have been explored for 
enhancing their potency [7, 8]. Our prior work has 
shown that radioimmunotherapy of mouse mammary 
tumor metastasis using α-emitter-labeled trastuzumab is 
superior to unlabeled-trastuzumab in terms of long-term 
survival [9, 10]. The efficacy of 225Ac, the parent of 213Bi, 
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was significantly superior to the other treatments using 
common β-emitter particles [10]. However, antibody-
bound 225Ac led to hematologic toxicity and free 213Bi 
arising from the decay of 225Ac in circulation accumulated 
in the kidneys and led to renal toxicity at high administered 
activities [9, 11]. We hypothesized that to circumvent renal 
and other systemic toxicity, localized delivery of 225Ac is 
an option worthy of investigation.
We have previously demonstrated the efficacy of 
intraductal administration (i.duc) of anticancer agents in 
the prevention and treatment of mammary tumors using 
rodent models [12–14]. The feasibility and safety of this 
method was demonstrated by us in Stage I breast cancer 
patients prior to mastectomy [14]. Since alpha particles 
can efficiently kill single cells and micro-tumors while 
sparing the surrounding normal tissues, delivery by the 
i.duc route could result in focusing its cytotoxic effects on 
the transformed, HER2 expressing ductal cells while also 
reducing systemic exposure [13, 14].
In this paper, we report the results of our 
investigation on whether the advantages of intraductal 
delivery could be leveraged for use in HER-2-targeted 
radioimmunotherapy for the treatment of mammary 
tumors in human HER-2 positive xenograft models. Based 
on promising results from preclinical studies, we propose 
that radioimmunotherapy by alpha-emitter radionuclides 
merits further investigation for future clinical applications.
RESULTS
Biodistribution of trastuzumab
The biodistribution of radio-immuno conjugates 
when injected locally by i.duc or systemically by i.v 
could be vastly different. Since this was the first attempt 
to administer the immunoconjugate i.duc, we studied 
biodistribution in more detail. We used 111In-trastuzumab 
to compare i.duc versus i.v biodistribution of the DOTA-
conjugated antibody in female FVB/N mice, the parental 
strain of origin of the NSG mice. 5.0-20.0 μCi was injected 
into the tail vein (120 μl) or the right 4th mammary gland 
(40 μl). The mean percentage of i.duc-injected 111In-
trastuzumab retained after administration in the right 4th 
mammary gland (%ID) was: 50.0% (SD, ± 25.0%) at 2 h, 
44.5% (SD, ± 25.9%) at 24 h and 30.9% (SD, ± 33.4%) 
at 120 h, and %ID/G was subsequently high only in the 
i.duc-injected mammary gland (Figure 1A). In contrast, 
i.v administration resulted in peaking of drug levels in 
the blood within 2 h, and distribution to all the organs of 
the body in near equal concentrations (Figure 1B). The 
AUC in blood following i.duc administration was 620 ± 
378 (SD) %ID/g-h versus 1220 ± 178 (SD) %ID/g-h for 
the i.v administration (p = 0.06). No acute hematological 
toxicity has been observed in prior murine studies with the 
blood AUC level observed following i.duc administration 
reported herein [11]. Thus, i.duc administration of 
the radioimmunoconjugate resulted in high localized 
concentration in the ductal system and reduced %ID/g 
in the other organs compared to systemic administration. 
These data suggested intraductal radioimmunotherapy 
may cause less systemic toxicity than the same dose of 
drug injected by the i.v. route. Further, a more sustained 
drug effect over a longer period of time may be achieved 
by the i.duc route.
Inhibition of colony formation by 
radioimmunoconjugate
In order to investigate if 225Ac-trastuzumab can 
inhibit growth of SUM225-Luc+, we performed colony 
formation assays. To ascertain the level of expression of 
HER2 in the cell lines under study, Western blotting was 
performed using SUM225, MCF-7 breast cancer cells, and 
a cell line derived from a MMTV-rat-neu transgenic mouse 
mammary tumor (Figure 2A). The results of the colony 
formation assay using Her2-overexpressing SUM225-
Luc+ cells showed that 225Ac-trastuzumab (D37 = 8.4 nCi/
ml) was about 9 times more lethal in colony formation 
assays (Survival fraction of 10 nCi/ml 225Ac-trastuzumab 
= 0.91) compared to the non-specific monoclonal antibody 
225Ac-rituximab (D37 = 71.4 nCi/ml) (Survival fraction 
of 10 nCi/ml 225Ac-Rituximab = 0.15) (Figure 2B). The 
contribution of unconjugated trastuzumab to cell death 
observed in this assay with the radioimmunoconjugate 
was evaluated by incubating SUM225-Luc+ cells with 
free trastuzumab (1 μg/ml) for 1 hour; colonies were 
observed in the range of 65-70% compared to 10% 
colonies observed with the radioimmunoconjugate 
(Figure 2C). The data showed that the specific affinity of 
trastuzumab to HER-2 was necessary to kill the HER-2 
positive cells. Further, with the additive effect of 225Ac, 
the radioimmunoconjugate was superior to treatment with 
excess trastuzumab.
Characterization of a mouse DCIS xenograft 
model, and intraductal immunotherapy
We adopted the previously described mouse 
xenograft model for DCIS [17] with some modifications. 
SUM225-Luc+ breast cancer cells were injected i.duc into 
4 inguinal mammary glands, and 10 μl of vehicle (Matrigel 
and complete media mixture) without cells was injected 
into the right and left 3rd mammary glands as controls. 
Nine NSG mice received intraductal injections; 3 mice 
each were examined by IVIS imaging (Figure S1) and 
were sacrificed at 7, 10 and 14 days after transplantation. 
IVIS imaging of the whole mouse detected tumor 
outgrowth in all four mammary glands by 7 days. At this 
time the outgrowths were not detected by palpation (Figure 
3A). At each time point following sacrifice, in each mouse, 
3 left mammary glands were examined by whole mount 
staining with carmine (Figure 3B, panel 1), the three 
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right mammary glands were examined by hematoxylin 
and eosin (H and E) staining (Figure 3B, panel 2) and 
by immunohistochemistry for the HER2 antigen (Figure 
3B, panel 3). With 3 mice for each time point, the 
distribution of tissues for the various tests was as follows: 
3 matrigel controls and 6 tumor cell injected mammary 
glands for whole mount, 3 controls and 6 tests each for 
H and E staining and HER2 IHC accounting for a total 
of 27 measurements at each time point. One week after 
transplantation, growth of the intraductal xenografts was 
observed as progressive thickening of the ducts over time 
by the whole mount analysis and as one to two cell layers 
within the duct by H and E staining. By IHC, SUM225 
cells stained strongly for HER2, and in some areas the 
Figure 1: Biodistribution of trastuzumab. %ID/g graphs show different patterns of biodistribution of trastuzumab at 2, 24, 120 hours 
after i.duc A. or tail vein B. injection (three mice per time point). The peak of %ID/g in the blood was 9.3 ± 5.3% at 24 hours after i.duc. 
%ID/g = (activity in each organ) X100/ (actual injected activity) per gram for each organ. Data are expressed as %ID/g+/-SD.
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i.duc implanted cells filled the duct. No microinvasion of 
the stroma by the tumor cells was observed. We concluded 
that the i.duc xenografts of SUM225-Luc+ cells in mice, 
one week after transplantation, served optimally as a 
model for DCIS for therapeutic studies.
For testing the efficacy of radioimmunotherapy, a 
week after i.duc implantation of SUM225-Luc+ tumor 
cells, NSG mice were randomly assigned to five groups 
before treatment. In each mouse, xenografts in three 
mammary glands were treated with 225Ac-trastuzumab 
(225Ac-T, specific activity: 0.1 μCi/μg) (Figure 4A). Ten, 
20 or 40 nCi of 225Ac-T/40 μl/teat was administered i.duc 
to groups of mice (n=3, 3, 4), respectively. 120 nCi of 
225Ac-T/120 μl per mouse was administered i.v to 3 mice 
for comparison with the i.duc mode of treatment, and 
40 μl of PBS/teat was administered i.duc to 4 teats of 3 
mice as vehicle controls. At 28 days after treatment, all 
i.duc 225Ac-T treated groups showed inhibition of tumor 
growth compared to i.v. 225Ac-T and i.duc PBS groups 
(p<0.0001) (Figure 4B) which carried large tumor 
burdens leading to the termination of the experiment. 
There was no significant difference in tumor burden by 
total flux measurements (Figure S2), but upon histological 
examination, we found tumor inhibiting efficacy was dose-
dependent, with 0/9 (10 nCi), 4/12 (20 nCi), and 11/12 (40 
nCi) tumor free mammary glands in each group (Table 
1). These results were confirmed by histopathology of 
the injected mammary glands (Figures 4C). In Figure 4C, 
representative micrographs of sections of mammary glands 
in tumor free mice (panel a, b) shows normal appearing 
ductal structures. Whole mount of the 4th and 5th mammary 
gland from the tumor bearing mouse in this group (40 nCi/
teat), shows tumor growth in the 4th mammary gland (the 
circled area), and the H and E stained section confirmed 
the presence of tumor cells in this lesion (panel c, d). 
Except for mice that received i.v. 225Ac-T, no appreciable 
weight loss was observed in the other treatment groups 
(Figure S2).
Figure 2: Colony formation assay with 225Ac-trastuzumab and 225Ac-rituximab. A. Western blot analysis of HER-2 protein 
in HER2-overexpressing human breast cancer cell line, SUM225, rat Her2-positive transgenic mouse mammary tumor cell lines (NT2.5 
and NT2.5-Luc+), and a low HER2-expressing human breast cancer cell line, MCF-7. B. Colony formation assay of SUM225-Luc+ cells 
with225Ac-trastuzumab and 225Ac-rituximab demonstrates HER-2-specific cell kill. Data is expressed as cell survival fraction ± SD. C. The 
contribution of unconjugated trastuzumab to cell death was tested by colony formation assay. SUM225-Luc+ cells were treated with cold 
trastuzumab (1 ug/ml) and 10 nCi/ml 225Ac-trastuzumab (1 ug/ml) for 1 hour. Data is expressed as cell survival fraction ± SD. (*P<0.001).
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Long-term carcinogenesis is of particular concern 
with alpha-particle emitters and there are a number of 
historical examples in which early use of alpha-emitters 
led to secondary cancers [10]. The extent to which these 
early examples are relevant to current use of alpha-
emitters in targeted therapy is under investigation [10]. We 
investigated long term toxicity of the 225Ac-Trastuzumab 
conjugate in the mammary gland and distant organs. 
We administrated 40 nCi of 225Ac-T/teat (3 teats in each 
mouse) i.duc once to female parous FVB/N mice (n=13) 
and monitored the mice monthly. There was no significant 
change in body weight during the 13 to 15 month 
observation period. However, tumors were observed in 
the mammary gland (1/39 mammary glands, 1/13 mice) 
and lung (4/13 mice), but not in the liver (0/13) and kidney 
(0/13) (Supplementary Table S2).
DISCUSSION
In this paper we report the results of testing the 
therapeutic effects of radioimmunotherapy with 225Ac-T 
delivered through the intraductal route in a HER-2 positive 
human DCIS xenograft model in immunodeficient female 
NSG mice. The DCIS xenograft mouse model provided 
Figure 3: Tumor development in the SUM225-Luc+ DCIS xenograft model. A. IVIS spectrum imaging shows representative 
tumor growth patterns in the mammary gland at 3 different time points after injection of SUM225-Luc+ cells through the teat. B. Panel 1: 
Whole mount staining performed 2 weeks after tumor cell inoculation showed enlarged buds and dilated ducts which increase in size with 
time. Panel 2: A single layer of SUM225 cells is seen attached to mouse epithelial layer of the mammary duct 1 week later, and tumor cells 
fill the ductal lumen 2 weeks later, as seen by H and E staining. Panel 3: Ductal outgrowths are HER2-positive by IHC. Bars indicate 100 
μm for whole mount and H&E staining, and 40 μm for HER-2 staining.
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Figure 4: Effects of radioimmunotherapy on intraductal DCIS xenograft model. A. IVIS spectrum imaging based 
evaluation of the mammary glands in the intact mice was performed just before treatment, and 10, 17 and 28 days after treatment with the 
immunoconjugate. IVIS shows all the mice in the 5 different groups at 28 days after treatment. Tumor growth is represented as total flux 
per mouse from IVIS at each time point. B. Data are expressed as total flux/mouse ± SD. C. Representative micrographs show two different 
mammary glands treated i.duc with 225Ac-trastuzumab (40 nCi/teat) (a, b). No tumors were visible in these mammary glands under IVIS 
spectrum imaging examination and by H and E staining. (c) The left 4th and 5th mammary glands were examined by H and E staining. A 
tumor focus (circle) was identified in the distal area of the left 4th mammary gland macroscopically (d) Microscopic examination revealed 
SUM225-Luc+ cell growth in the lumen. (e) All 9 mammary glands treated with 225Ac-trastuzumab (120 nCi/mouse/i.v) showed massive 
tumor lesions 28 days after intravenous treatment.
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mammary tumors at a noninvasive stage with high tumor 
take rates and allowed the study of HER-2 targeted 
intraductal therapy using 225Ac-T. Using this model, we 
also obtained data on the biodistribution, and therapeutic 
effectiveness of 225Ac-T at doses considerably lower than 
those used previously for systemic treatment.
The biodistribution studies highlighted the potential 
advantage of intraductal administration in that systemic 
exposure was substantially reduced relative to systemic 
administration of 225Ac-Trastuzumab, and the retention of 
trastuzumab remained at high levels even after 5 days. The 
therapeutic study using alpha-particle emitter conjugated 
trastuzumab showed that a total of 120 nCi of i.duc 225Ac-
Trastuzumab, distributed over three mammary glands 
inhibited tumor growth significantly more effectively than 
the same dose administered intravenously (Figure 4). Body 
weight loss during radioimmunotherapy was lower in the 
mice treated by the i.duc route compared to the i.v route. 
Thus, the therapeutic i.duc dose of radioimmunotherapy 
per teat was lower, which would likely result in reduced 
hematologic and renal toxicity.
In treating early disease like DCIS, long term 
toxicity of the therapeutic agent used is always of concern. 
This was borne out in our previous study in mice using 
Doxil i.duc [12]. Although highly effective in achieving 
long term cures in Her2-transgenic mouse tumors [13], 
i.duc Doxil induced mammary tumors in nearly 70% 
of naïve FVB/N mice, precluding its use through the 
intraductal route. 225Ac was significantly less carcinogenic 
in the mammary gland (1/39 mammary glands injected; 
1/13 mice), but induced lung tumors in 4/13 mice 
(Supplementary Table S2). Reducing the dose of the 
isotope may prevent its escape into the circulation, and 
eliminate local carcinogenic effects.
The i.duc route was used not only to establish the 
xenografts, but also to treat the xenografts repeatedly 
[12–14]. Successful repeated cannulation of the same duct 
with very high efficiency (97%), 6 months following the 
first cannulation, has been reported in disease free, high-
risk women in a chemoprevention setting [18]. Diseased 
ducts have been accessed successfully by cannulation for 
ductal lavage or ductoscopy as shown by us and others 
[14, 19–21]. Success has been reported in 40-95% of the 
cases with breast disease. As with all new technologies, 
wider experience with the technique will lead to better 
success rates.
We studied radioimmunotherapy using this model 
at 1 week after inoculation. IVIS spectrum imaging at 
one week after inoculation showed visible signals of 
luciferase activity in the inoculated mammary gland, and 
immunohistochemical staining showed that SUM225-Luc+ 
cells grew as a 1-2 layers on the mouse luminal epithelial 
cell layer, leaving ductal lumens open (Figure 3A, 3B). 
In addition, we observed that therapeutic efficacy of the 
i.duc 225Ac-trastuzumab was significantly higher than i.v 
administration (Figure 4), without attendant toxicity. These 
observations warrant further investigation. Given the 
short-range of the alpha-particles, micro-scale dosimetry 
will be needed to understand how to best translate these 
initial results to the clinic [22, 23]
In conclusion, the SUM225 xenograft model 
is useful to study treatment strategies for DCIS. We 
have provided evidence in this preclinical model for 
the potential of intraductal radioimmunotherapy using 
α-emitter particle 225Ac-labeled trastuzumab as a novel 
therapeutic alternative against DCIS of the breast.
MATERIALS AND METHODS
Cell lines
Human breast cancer cell lines, SUM-225 
(expressing high endogenous HER-2); MDA-MB-231 
and MCF-7 (low endogenous HER2) were maintained 
in culture according to instructions (ATCC). NT2.5, a 
cell line derived from Her-2/neu (rat) transgenic mouse 
mammary tumor, served as a murine negative control 
(trastuzumab does not bind the rat Her2 transgene). The 
Table 1: Response of SUM225 DCIS outgrowth to intraductally administered 225Ac-Trastuzumab conjugate
225Ac-Trastuzumab
Treatment PBS iduc 10 nCi iduc 20 nCi iduc 40 nCi iduc 120 nCi iv
Dose per mouse (nCi) 0 30 60 120 120
No. of mice 2 3 4 4 3 (2†)
No. of tumors/ No. of 
xenograft treated 8/8 9/9 8/12 1/12 9/9
Each of three to four mammary glands per mouse received 10,000 SUM225-Luc+ cells through the teat. All injected glands 
developed tumors along the ducts. In 225Ac-T treated mice, 3 tumor bearing mammary glands in each mouse received 225Ac-
Trastuzumab conjugate; 2 mice received PBS i.duc into four tumor bearing glands each.
†In mice receiving the conjugate i.v, 2/3 mice died before the end of the experiment at day 17 and 22 of follow up.
Statistical analyses presented in Supp. Tables S1-1 to S1-3
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cells were maintained in culture as previously described 
[9, 10].
Animal experiments
Eight to 12-month-old multiparous female mice 
were used in all the experiments, since prior lactation 
facilitated intraductal injection with ease and precision. 
Female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice were 
purchased (NSG mice, The Jackson Laboratory, USA) 
and bred at Johns Hopkins. Parous FVB/N female mice 
were purchased from NCI (Frederick, MD) and used in 
the biodistribution and long term toxicity study. All animal 
experiments were conducted following protocols approved 
by Animal Care and Use Committee of JHMI.
Antibodies
Trastuzumab (Herceptin, Genentech), an anti-
human HER-2 IgG monoclonal antibody, and Rituximab 
(Rituxan, IDEC Pharmaceutical Corp.), an anti-human 
CD20 IgG monoclonal antibody (non-specific antibody) 
were used.
Synthesis of 111In and 225Ac-labeled antibodies
In the biodistribution study, SCN-CHX-A”-
DTPA (Macrocyclics) was conjugated to antibody, and 
subsequently radiolabeled with 111In (2-10μCi/μg mAb) 
as described previously [9, 10]. 225Ac was provided by 
European Commission, Joint Research Centre, Institute 
for Transuranium Elements in Karlsruhe, Germany. In the 
therapeutic study, antibody was conjugated to p-SCN-Bn-
DOTA (Macrocyclics) and labeled with 225Ac by a 2-step 
method as described previously [9, 15]. Radiochemical 
yield of 225Ac-DOTA-Trastuzumab was 8.0-14.9% and 
the purity of 225Ac-DOTA-Trastuzumab was 95.1-98.7%; 
the specific activity of the labeled antibody was 1 μCi/μg 
mAb.
Biodistribution of trastuzumab
To examine the difference in pharmacokinetics of 
trastuzumab injected through two different routes, the 
antibody was radiolabeled with 111In and administered to 
multiparous female FVB/N wild-type mice (3 mice per 
group) bearing no tumors by i.v. or i.duc injection. At 2, 
24 and 120 hours after injection, mice were sacrificed 
and major organs and blood were collected. Each organ 
was measured by a gamma counter (LKB Wallac, Perkin-
Elmer). Results were corrected for physical decay 
and presented as percentage of injected dose per gram 
(%ID/g). The blood activity concentration profiles of the 
two different injection routes were compared by using 
numerical (trapezoidal) integration to obtain the area 
under the blood time-activity curve (AUC).
Intraductal transplantation method
Cells were detached from culture plates with 0.25% 
Trypsin/EDTA and resuspended as single cells in complete 
growth media and counted. The cell suspension (Matrigel: 
media =1:1) was placed on ice. A 50 μl Hamilton syringe 
with a 33-gauge Hamilton metal hub needle (7747-01, 
N733, point style 3, length 0.375 inches) chilled on ice 
was used to deliver the cells. The mice were anesthetized 
under an inhalation anesthesia (isoflurane, -2.0% and 
oxygen, 1.5L/min). Ten microliters of cell suspension was 
injected with visualization of the teat under a dissecting 
microscope (see Supplementary data, video showing 
methodology of i.duc injection into mouse teats).
Establishment of luciferase/GFP transfected cells
To enable visualization of the outgrowths, 
Luciferase and Green Fluorescent Protein (GFP) were 
introduced into SUM225 cells by retroviral infection. 
KMRV+Luciferase+GFP plasmid and Ampho-plasmid 
diluted in OPTi-MEM I were co-transfected into 293T 
cells with Lipofectamine TM 2000 (Invitrogen), following 
the manufacturers protocol. Luciferase-transfected 
(SUM225-Luc+) cells were sorted for GFP using FACS 
Diva Version 6.1.3. To visualize mouse intraductal DCIS-
like xenografts, Bioluminescent imaging using IVIS 
spectrum (Caliper, Life Sciences, software Living Imaging 
version 4.2) was conducted.
Mouse intraductal DCIS-like xenograft model
Ten thousand SUM225-Luc+ cells were transplanted 
by i.duc injection through the teat into each of 4 mammary 
glands of three 8-12 month old female NSG mice. Time 
course of tumor development was determined by staining 
formalin fixed, paraffin embedded mammary tissue with 
hematoxylin and eosin (H&E), HER-2 (primary Ab, Cell 
Signaling Technology, #2242, USA, 1:100 dilutions), red 
carmine for whole mounts, and IVIS spectrum imaging 
(IVIS). Histology was performed as described previously 
[14].
IVIS spectrum imaging
D-Luciferin, potassium Salt (Gold Biotechnology, 
LUCK) was dissolved in PBS without Mg2+ and Ca2+ 
at a concentration of 15 mg/ml. Mice received 10 μl 
of filtered D-Luciferin solution per gram body weight 
intraperitoneally (i.p) 10 minutes before imaging, 
and mice were then anesthetized. Two to five mice per 
one image acquisition were examined and all image 
acquisitions were performed at 30 seconds exposure 
(Xenogen IVIS Imaging System 100; data analysis using 
Caliper, Life Sciences, software Living Imaging version 
4.2). To compare each group, regions of interest (ROI) 
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were manually selected in squares, including whole body 
on the image of radiance. Total flux (photons/second) was 
measured corresponding to each ROI. All total fluxes were 
used for statistical analysis.
Specific cell kill in vitro by 225Ac-trastuzumab
Specific cell kill in vitro was determined by colony 
formation assays. SUM225 cells were seeded into 6-well 
plates at 0.4 to 5 X 103 cells per well, then treated with 
serially diluted 225Ac-trastuzumab or 225Ac-Rituximab (10-
30 nCi/ml). After incubation for one hour, SUM225 cells 
were trypsinized and replated on cell culture Petri dishes 
for colony growth. Cells were also treated with 1μg/ml 
cold-trastuzumab for one hour. Survival fraction was 
calculated using the CFU assay [16].
Intraductal radioimmunotherapy
40 μl of drug solution was injected into each of three 
inguinal mammary glands of each mouse as described 
previously [12–14]. Therapeutic experiments were 
performed to compare relative efficacy of i.duc compared 
to the i.v. route of administration.
Statistical analysis
Quantitative data were expressed as mean ± standard 
deviation (SD) or percentage when appropriate. Survival 
distributions were described using Kaplan-Meier method. 
Analyses of therapeutic efficacy involving the repeated 
measures data were performed using a hierarchical mixed 
effects model, where correlations among observations on 
the same animal were taken into account by assuming an 
exchangeable covariance structure. Treatment effects were 
assessed at different time points as total flux over time 
appeared to differ by treatment. Adjusted P values using 
Tukey’s procedure for multiple testing corrections were 
provided in addition to the exploratory unadjusted ones. 
Except for the blood AUC comparison, all statistical tests 
were two-sided. An unpaired, one tailed t-test was used to 
assess the significance of the difference in blood AUCs. 
We chose a one-tailed test because we expect that the AUC 
following i.duc administration will be lower than after 
IV administration. P<0.05 was considered statistically 
significant. The analyses were carried out using GraphPad 
Prism (v5.0, GraphPad Software, San Diego, CA), 
SAS software (v9.2, SAS Institute, Cary, NC) or Excel 
(Microsoft, Inc, Redmund WA).
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